ASCO: Pembrolizumab Ups DFS in High-Risk Resected Clear-Cell RCC

FRIDAY, June 4, 2021 -- For patients with fully resected intermediate-high-risk or high-risk clear-cell renal cell carcinoma (ccRCC), adjuvant therapy with pembrolizumab yields a significant and clinically meaningful improvement in disease-free...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news